Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Gibson

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Journal of Inorganic Biochemistry|August 2, 2005
Preparation, cytotoxicity and interactions with nucleophiles of three isomeric transplatinum complexes containing methylpiperidine ligandsSeba Jawbry, Inna Freikman, Yousef Najajreh, et al.
Journal of Medicinal Chemistry|September 8, 2016
A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor ActivityAiman Abu Ammar, Raji Raveendran, Dan Gibson, et al.
Dalton Transactions (Cambridge, England : 2003)|May 30, 2020
trans-Platinum(iv) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells: <sup>1</sup>H NMR and XANES spectroscopy studyCatherine K J Chen, Peter Kappen, Dan Gibson, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|December 3, 2002
Ligand effects on the binding of cis- and trans-[PtCl(2)Am(1)Am(2)] to proteinsYousef Najajreh, Tal Peleg-Shulman, Ofra Moshel, et al.
Journal of Medicinal Chemistry|January 15, 2026
A New Class of Multitargeting Pt<sup>IV</sup> Anticancer Agents: Prodrugs That Release Pt<sup>II</sup> Drugs and Bioactive Moieties Tethered to Pt<sup>IV</sup> via a Tertiary AmineMoumita Maji, Michele De Franco, Sourav Acharya, et al.
Journal of Medicinal Chemistry|November 11, 2020
Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer CellsSubhendu Karmakar, Hana Kostrhunova, Tereza Ctvrtlikova, et al.
Chemical Communications (Cambridge, England)|March 4, 2010
New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugsAlina Nemirovski, Inbal Vinograd, Khuloud Takrouri, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2005
Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in ratsEyal Sobol, Boris Yagen, Ilan Winkler, et al.
Chemical Research in Toxicology|October 14, 2010
Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitroHana Kostrhunova, Oldrich Vrana, Tereza Suchankova, et al.
Angewandte Chemie (International Ed. in English)|August 1, 2017
A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell LinesEmanuele Petruzzella, Jeremy Phillip Braude, Janice R Aldrich-Wright, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Journal of Inorganic Biochemistry|August 2, 2005
Preparation, cytotoxicity and interactions with nucleophiles of three isomeric transplatinum complexes containing methylpiperidine ligandsSeba Jawbry, Inna Freikman, Yousef Najajreh, et al.
Journal of Medicinal Chemistry|September 8, 2016
A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor ActivityAiman Abu Ammar, Raji Raveendran, Dan Gibson, et al.
Dalton Transactions (Cambridge, England : 2003)|May 30, 2020
trans-Platinum(iv) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells: <sup>1</sup>H NMR and XANES spectroscopy studyCatherine K J Chen, Peter Kappen, Dan Gibson, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|December 3, 2002
Ligand effects on the binding of cis- and trans-[PtCl(2)Am(1)Am(2)] to proteinsYousef Najajreh, Tal Peleg-Shulman, Ofra Moshel, et al.
Journal of Medicinal Chemistry|January 15, 2026
A New Class of Multitargeting Pt<sup>IV</sup> Anticancer Agents: Prodrugs That Release Pt<sup>II</sup> Drugs and Bioactive Moieties Tethered to Pt<sup>IV</sup> via a Tertiary AmineMoumita Maji, Michele De Franco, Sourav Acharya, et al.
Journal of Medicinal Chemistry|November 11, 2020
Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer CellsSubhendu Karmakar, Hana Kostrhunova, Tereza Ctvrtlikova, et al.
Chemical Communications (Cambridge, England)|March 4, 2010
New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugsAlina Nemirovski, Inbal Vinograd, Khuloud Takrouri, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2005
Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in ratsEyal Sobol, Boris Yagen, Ilan Winkler, et al.
Chemical Research in Toxicology|October 14, 2010
Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitroHana Kostrhunova, Oldrich Vrana, Tereza Suchankova, et al.
Angewandte Chemie (International Ed. in English)|August 1, 2017
A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell LinesEmanuele Petruzzella, Jeremy Phillip Braude, Janice R Aldrich-Wright, et al.
Pageof 9